Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

Eli Lilly's employment decisions under fire once ... For all of 2022, Lilly’s insulin products Humalog, Humulin and Basaglar posted sales declines of 16%, 17% and 15%, respectively.